Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).

被引：0
|
作者：
Qaisar, Aitzaz
Venugopal, Balaji
Ansel, Sonam
Jones, Robert J.
Slater, Sarah
Symeonides, Stefan N.
Malik, Jahangeer
Sundaramurthy, Aravindhan
Elliott, Tony
Devasar, Abeera
Stares, Mark
Randhawa, Manreet
机构：
[1] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2] Beatson Canc Ctr, Glasgow, Lanark, Scotland
[3] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[4] Edinburgh Canc Ctr, Edinburgh, Midlothian, Scotland
[5] Western Gen Hosp, Edinburgh, Midlothian, Scotland
[6] NHS Lothian, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
716
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
    Gruenwald, Viktor
    Merseburger, Axel S.
    ONCOTARGETS AND THERAPY, 2012, 5 : 111 - 117
  • [32] Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
    Iacovelli, R.
    Ciccarese, C.
    Bersanelli, M.
    Zucali, P. A.
    Fantinel, E.
    Bimbatti, D.
    Verzoni, E.
    Accettura, C.
    Bonomi, L.
    Buttigliero, C.
    Fornarini, G.
    Pipitone, S.
    Atzori, F.
    Masini, C.
    Massari, F.
    Primi, F.
    Buti, S.
    Perrino, M. R. A.
    Pafumi, S.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1013 - S1013
  • [33] Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies
    Denouel, Angeline
    Heutte, Natacha
    Escudier, Bernard
    Kurtz, Jean-Emmanuel
    Dos Santos, Melanie
    Longato, Nadine
    Desrues, Laurence
    Dauchy, Sarah
    Lange, Marie
    Sevin, Emmanuel
    Rieux, Chantal
    Clarisse, Benedicte
    Castel, Helene
    Noal, Sabien
    Joly, Florence
    CLINICAL GENITOURINARY CANCER, 2018, 16 (05) : 369 - +
  • [34] Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib?
    Keizman, Daniel
    Ish-Shalom, Maya
    Maimon, Natalie
    Gottfried, Maya
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Boursi, Ben
    Weitzen, Rony
    Hayat, Henry
    Peer, Avivit
    Neumann, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Mermershtain, Wilmosh
    Roubinov, Keren
    Carducci, Michael Anthony
    Berger, Raanan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [35] Peripheral immunomodulatory changes in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab
    Almeida, Lorena
    Maia, Manuel
    Won, Haejung
    Moreira, Dayson
    Bergerot, Paulo
    Kortylewski, Marcin
    Pal, Sumanta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [36] Brain metastases in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC)
    Alharbi, H.
    Choueiri, T. K.
    Kollmannsberger, C. K.
    North, S.
    MacKenzie, M. J.
    Knox, J. J.
    Rini, B. I.
    Heng, D. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [37] Novel risk scoring system for metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (C)
    Kline, Meredith R.
    Martini, Dylan J.
    Liu, Yuan
    Shabto, Julie M.
    Carthon, Bradley Curtis
    Hitron, Elise
    Russler, Greta
    Caulfield, Sarah
    Yantorni, Lauren Beth
    Harris, Wayne
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] Sinus Bradycardia With Pauses Owing to Axitinib/Pembrolizumab in a Metastatic Renal Cell Carcinoma Patient
    McGreevy, Joseph W.
    Ghous, Ghulam
    Shoukat, Hafiz Muhammad Hassan
    Zafar, Muhammad Usman
    Tarar, Zahid Ijaz
    AMERICAN JOURNAL OF THERAPEUTICS, 2023, 30 (03) : E304 - E305
  • [39] Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
    Olsen, T. Anders
    Martini, Dylan J.
    Evans, Sean T.
    Goldman, Jamie M.
    Bilen, Mehmet Asim
    JOURNAL OF MEDICAL CASE REPORTS, 2021, 15 (01)
  • [40] Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.
    Ohm, Hyejee
    Ghosh, Sunita
    Gupta, Mehul
    Wood, Lori
    Castonguay, Vincent
    Graham, Jeffrey
    Kollmannsberger, Christian K.
    Bosse, Dominick
    Soulieres, Denis
    Heng, Daniel Yick Chin
    Fallah-Rad, Nazanin
    Finelli, Antonio
    Tanguay, Simon
    Lalani, Aly-Khan A.
    Bhindi, Bimal
    Bjarnason, Georg A.
    Breau, Rodney H.
    Pouliot, Frederic
    Basappa, Naveen S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 393 - 393
12345